UAE Approves First Oral Obesity Treatment Pill: Legal and Regulatory Implications

The UAE has approved its first oral obesity treatment pill, Foundayo (orforglipron), through the Emirates Drug Establishment (EDE).

This approval has been granted under Federal Law No. (8) of 2019 on Medical Products, Pharmacy Profession and Pharmaceutical Establishments, which regulates the approval, sale, and use of medicines in the UAE.

While the development is medically significant, it also raises important legal considerations relating to prescription control, eligibility, and compliance obligations.

Regulatory Approval under UAE Law

Under UAE law, pharmaceutical products cannot be introduced into the market without prior approval from the competent authority.

The approval of Foundayo confirms that the drug has met the required standards for safety and controlled use. It also means that its distribution and use will remain subject to the provisions of Federal Law No. (8) of 2019, including rules on prescribing, dispensing, and monitoring.

A Shift in Treatment Approach

The approval reflects a broader shift in how obesity is treated in the UAE.

Rather than being viewed only as a lifestyle issue, obesity is now increasingly treated as a medical condition requiring structured and supervised treatment. As a result, access to such medication is no longer informal and is instead governed by clear medical and legal requirements.

This places greater responsibility on healthcare professionals to ensure that treatment is prescribed only where medically justified.

Eligibility for Use

The use of this medication is restricted to specific patient categories. It is generally prescribed in the following cases:

• individuals with a BMI of 30 or above; or

• individuals with a BMI of 27 or above along with related conditions such as diabetes or hypertension

This makes it clear that the medication is not intended for general or cosmetic weight loss. Its use must remain within defined clinical limits.

Prescription and Dispensing Requirements

Foundayo is classified as a prescription-only medication.

This means that it can only be prescribed by licensed medical professionals and dispensed through authorised pharmacies. The law requires that prescriptions are based on proper medical assessment, and pharmacies must ensure that dispensing is supported by valid documentation.

Any deviation from these requirements, including unauthorised dispensing or inappropriate prescription, may result in regulatory action.

Availability and Access

The medication is expected to become available through licensed hospitals, clinics, and pharmacies.

However, its actual accessibility will depend on factors such as pricing, insurance coverage, and supply. These factors will play an important role in determining how widely the treatment is used in practice.

Compliance and Legal Responsibility

Legal responsibility does not end with approval. It extends to how the medication is prescribed and used.

Risk may arise in situations involving:

• prescription outside approved medical criteria;

• dispensing without valid prescription; or

• use for non-medical purposes

Healthcare providers and pharmacies must therefore ensure that all legal and clinical requirements are strictly followed.

Conclusion

The approval of Foundayo highlights a clear direction in the UAE’s healthcare system—greater reliance on regulated, medically supervised treatment.

While access to advanced treatment is increasing, it is accompanied by stricter control over how such treatment is prescribed and used.

The key takeaway is simple:
greater access does not reduce regulation—it increases the need for compliance.